Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Nippon Shinyaku's Brogidirsen?
Brogidirsen is an antisense oligonucleotide commercialized by Nippon Shinyaku, with a leading Phase II program in Duchenne Muscular Dystrophy. According...
Data Insights
Brogidirsen by Nippon Shinyaku for Duchenne Muscular Dystrophy: Likelihood of Approval
Brogidirsen is under clinical development by Nippon Shinyaku and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData,...